Motor Neuron Disease Clinical Trial
Official title:
Electrical Impedance Myography: Natural History Studies in Neuromuscular Disorders and Healthy Volunteers
Background: - Electrical impedance myography (EIM) is a new technique being studied to see if it is helpful in evaluating muscle disorders and nerve disorders. EIM looks at how a mild, painless electrical current travels through muscles. Researchers want to gain experience in using the EIM device. They will collect information on the results of using it on people with and without nerve and muscle diseases, and compare that with information from other standard tests. First, they will test the device on healthy people. Then they will test people with a variety of neuromuscular diseases. Because the test is noninvasive and not painful, researchers will test both children and adults. Objectives: - To gain experience using the EIM muscle testing device. Eligibility: - Healthy volunteers at least 2 years old. - Individuals at least 2 years old who have neuromuscular disease. Design: - Participants will be screened with a medical history and physical exam. - Participants will have one 2-3 hour clinic visit. Researchers may request follow-up visits. - Participants will be tested with the EIM device. The device and small electrodes will be placed on their skin. An electric current will pass through the device, but the participants will not feel this. - Participants may have an ultrasound test. A gel will be put on their skin, and a device will be moved over the skin. - Participants may have a nerve test. Electrodes will be placed on their skin, and they will feel a small shock. - Participants may have a test where a thin needle is inserted in their muscle.
Status | Recruiting |
Enrollment | 275 |
Est. completion date | December 1, 2024 |
Est. primary completion date | December 1, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 2 Years to 110 Years |
Eligibility | - INCLUSION CRITERIA: HEALTHY VOLUNTEERS-ADULTS 1. Healthy adults, male or female, aged 18 years old or older, 2. In good general health as evidenced by medical history 3. Stated willingness to comply with all study procedures and availability for the duration of the study. 4. Ability of subject to understand and the willingness to sign a written informed consent document. HEALTHY VOLUNTEERS-PEDIATRIC 1. Healthy children, male or female, age 7-18, 2. In good general health as evidenced by medical history 3. Stated willingness to comply with all study procedures and availability for the duration of the study 4. Ability of subject or Legally Authorized Representative (LAR)) to understand and the willingness to sign a written informed consent document. SUBJECTS WITH NEUROMUSCULAR DISEASE Adult and pediatric, male or female, patients with a neuromuscular disorder are eligible even if the exact etiology of the disorder is unknown at the time of enrollment into this study. This will include neuropathy, myopathy and motor neuron disorders. It is expected that the subjects are undergoing appropriate standard diagnostic and genetic work-up outside of this protocol that will later clarify the specific etiology of the disorder. Movement disorder will also be included because of the prior research done on dystonia and EIM. Inclusion criteria 1. Suspected motor neuron disease or 2. Suspected myopathy or 3. Suspected neuropathy or 4. Suspected movement disorders that impair intracortical processes 5. Age of 2 years or older 6. Ability of subject to sign a written informed consent document. NIH EMPLOYEES: NIH employees and staff may participate, however EMG Section, OCD, NINDS, employees may not participate. EXCLUSION CRITERIA: HEALTHY VOLUNTEERS-ADULTS 1. Medical conditions that require medications that affects the physiological measures being tested. Some conditions that may be excluded are diabetes, kidney and liver disease. 2. History of stroke, muscle disorders, peripheral neuropathy or spine surgery HEALTHY VOLUNTEERS-PEDIATRIC 1. Medical conditions that require medications that affects the physiological measures being tested. Some conditions that may be excluded are diabetes, kidney and liver disease. 2. History of stroke, muscle disorders, peripheral neuropathy or spine surgery SUBJECTS WITH NEUROMUSCULAR DISEASE: No clinical evidence of a neuromuscular disorder on clinical evaluation. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Neurological Disorders and Stroke (NINDS) |
United States,
Nichols C, Jain MS, Meilleur KG, Wu T, Collins J, Waite MR, Dastgir J, Salman A, Donkervoort S, Duong T, Keller K, Leach ME, Lott DJ, McGuire MN, Nelson L, Rutkowski A, Vuillerot C, Bonnemann CG, Lehky TJ. Electrical impedance myography in individuals with collagen 6 and laminin alpha-2 congenital muscular dystrophy: a cross-sectional and 2-year analysis. Muscle Nerve. 2018 Jan;57(1):54-60. doi: 10.1002/mus.25629. Epub 2017 Apr 25. — View Citation
Offit MB, Wu T, Floeter MK, Lehky TJ. Electrical impedance myography (EIM) in a natural history study of C9ORF72 mutation carriers. Amyotroph Lateral Scler Frontotemporal Degener. 2020 Aug;21(5-6):445-451. doi: 10.1080/21678421.2020.1752247. Epub 2020 Apr 21. — View Citation
Schwartz DP, Dastgir J, Salman A, Lear B, Bonnemann CG, Lehky TJ. Electrical impedance myography discriminates congenital muscular dystrophy from controls. Muscle Nerve. 2016 Mar;53(3):402-6. doi: 10.1002/mus.24770. Epub 2015 Aug 13. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Patients - EIM measures for a selection of muscles | Obtaining measures using EIM device in different types of neuromuscular disorders. | End of study | |
Primary | Healthy Volunteers - EIM measures for a selection of muscles with the aim of developing normative values for the NIH EMG lab | Obtaining measures using EIM device- reproducibility and normative data | End of study | |
Secondary | Serial studies in pediatric patients | Serial measures of EIM in patients with neuromuscular disorders | End of study | |
Secondary | Healthy Volunteers - exploratory correlations of ultrasound and electrodiagnostic methods such nerve conduction studies and less likely, EMG | Obtaining measures using EIM device and comparing with ultrasound and motor unit number estimation techniques. | End of study |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04579666 -
MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
Completed |
NCT03706391 -
Study of ALS Reversals 4: LifeTime Exposures
|
||
Active, not recruiting |
NCT03067857 -
Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02464748 -
Telehealth in Motor Neurone Disease
|
N/A | |
Completed |
NCT00956488 -
Supported Treadmill Ambulation Training (STAT) for Patients Diagnosed With Amyotrophic Lateral Aclerosis
|
Phase 1/Phase 2 | |
Terminated |
NCT00537446 -
Effect of Noninvasive Ventilation on Lung Function in Amyotrophic Lateral Sclerosis
|
N/A | |
Recruiting |
NCT04944940 -
Clinical, Molecular and Imaging Biomarkers in Spinal and Bulbar Muscular Atrophy (SBMA)
|
||
Recruiting |
NCT03362658 -
Novel MRI Biomarkers for Monitoring Disease Progression in ALS
|
||
Completed |
NCT00714636 -
Cerebrospinal Fluid Repository
|
N/A | |
Completed |
NCT00071435 -
Brain Function in Primary Lateral Sclerosis
|
N/A | |
Completed |
NCT00076687 -
Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function
|
Phase 2 | |
Completed |
NCT00001220 -
Ultrasound and Videofluoroscopy for Diagnosing Swallowing Disorders
|
N/A | |
Completed |
NCT03487263 -
Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease
|
Phase 1 | |
Enrolling by invitation |
NCT05725759 -
Rehabilitation in SOD1 ALS Treated With Tofersen
|
||
Active, not recruiting |
NCT03811301 -
[BrainConnexion] - Neurodevice Phase I Trial
|
N/A | |
Completed |
NCT02469896 -
A Trial of Tocilizumab in ALS Subjects
|
Phase 2 | |
Completed |
NCT02011204 -
Study of Electrical Impedance Myography (EIM) in ALS
|
N/A | |
Completed |
NCT01495390 -
A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers
|
N/A | |
Completed |
NCT02870634 -
Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND
|
Phase 1 | |
Recruiting |
NCT06201650 -
Neurofilament Light Chain in Amyotrophic Lateral Sclerosis
|